Maël Heiblig

25PUBLICATIONS
303CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyMedical infection agents (incl. prions)PharmacogenomicsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Sep 04, 2026
Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|May 21, 2026
Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

|Feb 27, 2026
PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome.

David B Beck, Maël Heiblig, Sinisa Savic

|Nov 25, 2025
Establishing a consensus definition of VEXAS flare for clinical research.

Lachelle D Weeks, Danielle Hammond, Sinisa Savic

|Sep 25, 2025
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.

Eunice S Wang, Pau Montesinos, James Foran

Pageof 5

Frequent Collaborators

6 joint publications

Arsene Mekininan

5 joint publications

Emmanuelle Tavernier-Tardy

5 joint publications

Pierre-Yves Dumas

5 joint publications

Thibault Comont